Special Issue: Design of Bioreactor Systems for Tissue Engineering

Abstract

Tissue engineering and, more broadly, regenerative medicine is moving into a phase where we are seeing potential therapies moving ‘slowly but surely’ from the laboratory into the clinic, i.e., from research to the clinic and into manufacturing. The numbers of cells required for cell therapy protocols can vary from tens of millions, to billions [1], and it is widely considered that such cell numbers can be produced in bioreactor systems. Thus, the bioreactor is becoming a key tool for culturing clinical numbers of human cells and the regenerative medicine industry will become increasingly reliant on such systems at the centre of cell therapy production and tissue engineering.[...]